Does the media favor ELTX or PRQR?

In the previous week, Elicio Therapeutics and Elicio Therapeutics both had 3 articles in the media. ProQR Therapeutics' average media sentiment score of 0.45 beat Elicio Therapeutics' score of 0.34 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate ORMP or ELTX?

Elicio Therapeutics has a consensus price target of $19.75, indicating a potential upside of 956.15%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Elicio Therapeutics is more favorable than Oramed Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oramed Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Elicio Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings & valuation, ORMP or ELTX?

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oramed Pharmaceuticals N/A N/A $64.05M $4.12 1.15 Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A

Is ORMP or ELTX more profitable?

Oramed Pharmaceuticals' return on equity of -5.17% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oramed Pharmaceuticals N/A -5.17% -4.54% Elicio Therapeutics N/A -1,266.43% -139.94%

Does the media refer more to CHRS or ELTX?

In the previous week, Coherus Oncology and Coherus Oncology both had 3 articles in the media. Coherus Oncology's average media sentiment score of 0.67 beat Elicio Therapeutics' score of 0.34 indicating that Coherus Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coherus Oncology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VYGR or ELTX?

In the previous week, Elicio Therapeutics had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Elicio Therapeutics and 1 mentions for Voyager Therapeutics. Elicio Therapeutics' average media sentiment score of 0.34 beat Voyager Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, ELTX or ABOS?

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elicio Therapeutics N/A N/A -$39.57M -$2.17 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.63 N/A

Is ELTX or ABOS more profitable?

Acumen Pharmaceuticals' return on equity of -136.27% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% Acumen Pharmaceuticals N/A -136.27% -81.64%

Does the media favor ELTX or ABOS?

In the previous week, Elicio Therapeutics and Elicio Therapeutics both had 3 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 0.78 beat Elicio Therapeutics' score of 0.34 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elicio Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acumen Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Elicio Therapeutics (ELTX) Competitors

$1.87 0.00 (0.00%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.00 (+0.27%)

As of 04:02 AM Eastern

Compare

ELTX vs. PRQR, ORMP, CHRS, VYGR, and ABOS

Should you buy Elicio Therapeutics stock or one of its competitors? Elicio Therapeutics's main competitors and comparable companies include ProQR Therapeutics (PRQR), Oramed Pharmaceuticals (ORMP), Coherus Oncology (CHRS), Voyager Therapeutics (VYGR), and Acumen Pharmaceuticals (ABOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Elicio Therapeutics compare to ProQR Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Elicio Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market.

Elicio Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. ProQR Therapeutics' return on equity of -73.83% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

In the previous week, Elicio Therapeutics and Elicio Therapeutics both had 3 articles in the media. ProQR Therapeutics' average media sentiment score of 0.45 beat Elicio Therapeutics' score of 0.34 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Elicio Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
ProQR Therapeutics	$18.36M	9.75	-$47.73M	-$0.46	N/A

Elicio Therapeutics currently has a consensus price target of $19.75, suggesting a potential upside of 956.15%. ProQR Therapeutics has a consensus price target of $7.50, suggesting a potential upside of 341.18%. Given Elicio Therapeutics' higher probable upside, research analysts plainly believe Elicio Therapeutics is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Elicio Therapeutics and ProQR Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Oramed Pharmaceuticals?

Oramed Pharmaceuticals (NASDAQ:ORMP) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Oramed Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Oramed Pharmaceuticals' return on equity of -5.17% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

In the previous week, Elicio Therapeutics had 3 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 3 mentions for Elicio Therapeutics and 0 mentions for Oramed Pharmaceuticals. Elicio Therapeutics' average media sentiment score of 0.34 beat Oramed Pharmaceuticals' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Oramed Pharmaceuticals	Neutral
Elicio Therapeutics	Neutral

Elicio Therapeutics is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oramed Pharmaceuticals	N/A	N/A	$64.05M	$4.12	1.15
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Elicio Therapeutics has a consensus price target of $19.75, indicating a potential upside of 956.15%. Given Elicio Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Elicio Therapeutics is more favorable than Oramed Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oramed Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Elicio Therapeutics beats Oramed Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Elicio Therapeutics compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Coherus Oncology currently has a consensus target price of $11.00, indicating a potential upside of 773.02%. Elicio Therapeutics has a consensus target price of $19.75, indicating a potential upside of 956.15%. Given Elicio Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Elicio Therapeutics is more favorable than Coherus Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 7.2% of Coherus Oncology shares are owned by insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Elicio Therapeutics has a net margin of 0.00% compared to Coherus Oncology's net margin of -259.41%. Coherus Oncology's return on equity of -222.75% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	-259.41%	-222.75%	-52.11%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

In the previous week, Coherus Oncology and Coherus Oncology both had 3 articles in the media. Coherus Oncology's average media sentiment score of 0.67 beat Elicio Therapeutics' score of 0.34 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coherus Oncology has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Elicio Therapeutics. Coherus Oncology is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	4.62	$168.02M	-$1.03	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Summary

Coherus Oncology and Elicio Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Elicio Therapeutics compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Elicio Therapeutics (NASDAQ:ELTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Voyager Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Elicio Therapeutics has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Elicio Therapeutics has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -312.63%. Voyager Therapeutics' return on equity of -57.92% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Elicio Therapeutics	N/A	-1,266.43%	-139.94%

In the previous week, Elicio Therapeutics had 2 more articles in the media than Voyager Therapeutics. MarketBeat recorded 3 mentions for Elicio Therapeutics and 1 mentions for Voyager Therapeutics. Elicio Therapeutics' average media sentiment score of 0.34 beat Voyager Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Voyager Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 474.91%. Elicio Therapeutics has a consensus price target of $19.75, indicating a potential upside of 956.15%. Given Elicio Therapeutics' higher possible upside, analysts plainly believe Elicio Therapeutics is more favorable than Voyager Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 35.0% of Elicio Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 50.9% of Elicio Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Elicio Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Voyager Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$40.37M	4.38	-$119.72M	-$1.80	N/A
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A

Summary

Voyager Therapeutics and Elicio Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Elicio Therapeutics compare to Acumen Pharmaceuticals?

Elicio Therapeutics (NASDAQ:ELTX) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Elicio Therapeutics has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

In the previous week, Elicio Therapeutics and Elicio Therapeutics both had 3 articles in the media. Acumen Pharmaceuticals' average media sentiment score of 0.78 beat Elicio Therapeutics' score of 0.34 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elicio Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Acumen Pharmaceuticals' return on equity of -136.27% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Acumen Pharmaceuticals	N/A	-136.27%	-81.64%

35.0% of Elicio Therapeutics shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 50.9% of Elicio Therapeutics shares are owned by company insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.63	N/A

Elicio Therapeutics presently has a consensus target price of $19.75, suggesting a potential upside of 956.15%. Acumen Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 203.03%. Given Elicio Therapeutics' higher probable upside, equities analysts plainly believe Elicio Therapeutics is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Acumen Pharmaceuticals beats Elicio Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Elicio Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELTX vs. The Competition

Export

Metric	Elicio Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$49.15M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.86	13.88	274.09	25.69
Price / Sales	N/A	1,353.16	642.55	79.71
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	20.78	15.40	10.47	6.32
Net Income	-$39.57M	-$22.82M	$3.49B	$359.73M
7 Day Performance	0.27%	-1.74%	-0.68%	0.17%
1 Month Performance	-37.25%	-6.20%	-3.18%	-3.27%
1 Year Performance	-83.14%	30.64%	15.12%	5.58%

Elicio Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELTX Elicio Therapeutics	2.5615 of 5 stars	$1.87 flat	$19.75 +956.1%	-83.2%	$49.15M	N/A	N/A	N/A	News Coverage Positive News Gap Down
PRQR ProQR Therapeutics	3.9845 of 5 stars	$1.89 +1.6%	$7.50 +296.8%	-21.3%	$195.98M	$18.36M	N/A	166	News Coverage
ORMP Oramed Pharmaceuticals	1.5479 of 5 stars	$4.67 +1.1%	N/A	+89.6%	$192.18M	$2M	1.13	13
CHRS Coherus Oncology	2.0973 of 5 stars	$1.23 +0.8%	$11.00 +794.3%	-19.2%	$188.49M	$42.17M	N/A	144	News Coverage Analyst Downgrade High Trading Volume
VYGR Voyager Therapeutics	2.6255 of 5 stars	$3.04 -0.3%	$16.50 +442.8%	-30.0%	$187.93M	$40.37M	N/A	141

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELTX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elicio Therapeutics (ELTX) Competitors

ELTX vs. PRQR, ORMP, CHRS, VYGR, and ABOS

How does Elicio Therapeutics compare to ProQR Therapeutics?

Summary

How does Elicio Therapeutics compare to Oramed Pharmaceuticals?

Summary

How does Elicio Therapeutics compare to Coherus Oncology?

Summary

How does Elicio Therapeutics compare to Voyager Therapeutics?

Summary

How does Elicio Therapeutics compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elicio Therapeutics (ELTX) Competitors

ELTX vs. PRQR, ORMP, CHRS, VYGR, and ABOS

How does Elicio Therapeutics compare to ProQR Therapeutics?

Which has more risk and volatility, ELTX or PRQR?

Is ELTX or PRQR more profitable?

Does the media favor ELTX or PRQR?

Do institutionals and insiders hold more shares of ELTX or PRQR?

Which has preferable earnings and valuation, ELTX or PRQR?

Do analysts prefer ELTX or PRQR?

Summary

How does Elicio Therapeutics compare to Oramed Pharmaceuticals?

Which has more risk and volatility, ORMP or ELTX?

Is ORMP or ELTX more profitable?

Does the media refer more to ORMP or ELTX?

Which has better earnings & valuation, ORMP or ELTX?

Do analysts rate ORMP or ELTX?

Do institutionals & insiders have more ownership in ORMP or ELTX?

Summary

How does Elicio Therapeutics compare to Coherus Oncology?

Do analysts recommend CHRS or ELTX?

Do insiders & institutionals have more ownership in CHRS or ELTX?

Is CHRS or ELTX more profitable?

Does the media refer more to CHRS or ELTX?

Which has more risk & volatility, CHRS or ELTX?

Which has preferable valuation & earnings, CHRS or ELTX?

Summary

How does Elicio Therapeutics compare to Voyager Therapeutics?

Which has more volatility & risk, VYGR or ELTX?

Is VYGR or ELTX more profitable?

Does the media refer more to VYGR or ELTX?

Do analysts recommend VYGR or ELTX?

Do insiders and institutionals have more ownership in VYGR or ELTX?

Which has stronger valuation and earnings, VYGR or ELTX?

Summary

How does Elicio Therapeutics compare to Acumen Pharmaceuticals?

Which has more risk and volatility, ELTX or ABOS?

Does the media favor ELTX or ABOS?

Is ELTX or ABOS more profitable?

Do institutionals & insiders hold more shares of ELTX or ABOS?

Which has preferable earnings & valuation, ELTX or ABOS?

Do analysts recommend ELTX or ABOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELTX vs. The Competition

Elicio Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools